tiprankstipranks
Stock Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksStock ScreenerCompare StocksPenny Stock ScreenerTop Product Insights Stocks
Daily Updates
Daily Analyst RatingsTrending StocksTop Stock GainersTop Stock LosersMost Active StocksDividend StocksChatGPT Stocks
New
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarMarket Holidays
ETF Research Tools
ETF CenterETF ScreenerTop ETFs by Smart Score
New
Compare ETFsTop ETFs by AUM
ETFs On the Move
Top ETF GainersTop ETF LosersMost Active ETFs
ETF Ideas
S&P 500 Index ETFsNasdaq 100 Index ETFsS&P 500 Sector ETFsBond ETFsCommodity ETFsCurrency ETFsIndustry ETFs
Best Dividend StocksBest High Yield Dividend StocksDividend Aristocrats
New
Dividend Stock ComparisonDividend Calculator
Popular
Dividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
My PortfolioMy WatchlistMy PerformanceMy Portfolio AnalysisCrowd Insights
Stock Market NewsStock Analysis & Ideas
Popular
ETF NewsGlobal Markets NewsExpert SpotlightTipRanks LabsEarnings Reports InsightsMarket BreakdownsDividend Stock NewsCrypto News
Education
TipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksTipRanks CommunityCareersContact Us
Working with TipRanks
Enterprise SolutionsBest Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert Center
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
ETF Center
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Stock Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Stock Screener
Compare Stocks
Penny Stock Screener
Top Product Insights Stocks
Options Profit Calculator
New
Daily Updates
Daily Analyst Ratings
Trending Stocks
Top Stock Gainers
Top Stock Losers
Most Active Stocks
Dividend Stocks
ChatGPT Stocks
New
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Market Holidays
ETF Research Tools
ETF Center
ETF Screener
New
Top ETFs by Smart Score
New
Compare ETFs
Top ETFs by AUM
ETFs On the Move
Top ETF Gainers
Top ETF Losers
Most Active ETFs
ETF Ideas
S&P 500 Index ETFs
Nasdaq 100 Index ETFs
S&P 500 Sector ETFs
Bond ETFs
Commodity ETFs
Currency ETFs
Industry ETFs
Best Dividend Stocks
Best High Yield Dividend Stocks
Dividend Aristocrats
New
Dividend Stock Comparison
Dividend Calculator
Popular
Dividend Returns Comparison
Dividend Calendar
Crypto Center
Bitcoin
Ethereum
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
My Portfolio
My Watchlist
My Performance
My Portfolio Analysis
Crowd Insights
Stock Market News
Stock Analysis & Ideas
Popular
ETF News
Global Markets News
Expert Spotlight
TipRanks Labs
Earnings Reports Insights
Market Breakdowns
Dividend Stock News
Crypto News
Education
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
TipRanks Community
Careers
Contact Us
Working with TipRanks
Enterprise Solutions
Best Online Brokers
Become an Affiliate
Follow Us
Plans & Pricing

AMRN Stock Latest News

Amarin to Present at Two Upcoming Investor Conferences
Press ReleasesAmarin to Present at Two Upcoming Investor Conferences
8d ago
AMRN
Amarin Partner EddingPharm Receives Regulatory Approval for Vascepa® (Icosapent Ethyl) in Mainland China
Press ReleasesAmarin Partner EddingPharm Receives Regulatory Approval for Vascepa® (Icosapent Ethyl) in Mainland China
8d ago
AMRN
Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events
Press ReleasesAmarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events
28d ago
AMRN
Amarin Reports First Quarter 2023 Financial Results and Provides Business Update
Press ReleasesAmarin Reports First Quarter 2023 Financial Results and Provides Business Update
1M ago
AMRN
Amarin cuts FY23 operating expense guidance to $270M-$285M from $290M-$305M
The FlyAmarin cuts FY23 operating expense guidance to $270M-$285M from $290M-$305M
1M ago
AMRN
Amarin reports Q1 adjusted EPS 2c, consensus (3c)
The FlyAmarin reports Q1 adjusted EPS 2c, consensus (3c)
1M ago
AMRN
Amarin to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023
Press ReleasesAmarin to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023
2M ago
AMRN
Amarin Names Aaron Berg Interim President & Chief Executive Officer and Adds Oliver O’Connor to Company’s Board of Directors
Press ReleasesAmarin Names Aaron Berg Interim President & Chief Executive Officer and Adds Oliver O’Connor to Company’s Board of Directors
2M ago
AMRN
Amarin adds O’Connor to board of directors
The FlyAmarin adds O’Connor to board of directors
2M ago
AMRN
Amarin names Berg interim President, CEO
The FlyAmarin names Berg interim President, CEO
2M ago
AMRN
Amarin announces VAZKEPA approved by Israel’s MOH
The FlyAmarin announces VAZKEPA approved by Israel’s MOH
2M ago
AMRN
Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved by Israel’s Ministry of Health
Press ReleasesAmarin Announces VAZKEPA® (Icosapent Ethyl) Approved by Israel’s Ministry of Health
2M ago
AMRN
Amarin says board ‘ready’ to unlock true potential of VASCEPA/VAZKEPA
The FlyAmarin says board ‘ready’ to unlock true potential of VASCEPA/VAZKEPA
3M ago
AMRN
Amarin Announces Board Departures
Press ReleasesAmarin Announces Board Departures
3M ago
AMRN
Amarin announces new in vitro data on eicosapentaenoic acid
The FlyAmarin announces new in vitro data on eicosapentaenoic acid
3M ago
AMRN
Amarin announces new REDUCE-IT data at ACC.23/WCC
The FlyAmarin announces new REDUCE-IT data at ACC.23/WCC
3M ago
AMRN
Amarin Announces New REDUCE-IT® Data at ACC.23/WCC Showing Benefit of VASCEPA®/VAZKEPA® (Icosapent Ethyl) in High-Risk Patients with a Recent Acute Coronary Syndrome Event
Press ReleasesAmarin Announces New REDUCE-IT® Data at ACC.23/WCC Showing Benefit of VASCEPA®/VAZKEPA® (Icosapent Ethyl) in High-Risk Patients with a Recent Acute Coronary Syndrome Event
3M ago
AMRN
Amarin Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Press ReleasesAmarin Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
3M ago
AMRN
Amarin expects cash to support continued operations, including European launch
The FlyAmarin expects cash to support continued operations, including European launch
3M ago
AMRN
Amarin reports Q4 adjusted EPS 2c, consensus 0c
The FlyAmarin reports Q4 adjusted EPS 2c, consensus 0c
3M ago
AMRN
Amarin Announces Preliminary Voting Results Following 2023 General Meeting of Shareholders
Press ReleasesAmarin Announces Preliminary Voting Results Following 2023 General Meeting of Shareholders
3M ago
AMRN
Sarissa Capital announces proxy contest win against Amarin
The FlySarissa Capital announces proxy contest win against Amarin
3M ago
AMRN